ClinicalTrials.gg
CompletedNCT00619697EUROMIXUpdated Jan 6, 2017

Efficacy and Safety of Biphasic Insulin Aspart 30 in Combination With Metformin in Type 2 Diabetes

A Phase 4 interventional study of biphasic insulin aspart and insulin glargine in Diabetes and Diabetes Mellitus, Type 2, sponsored by Novo Nordisk A/S. Completed at 54 sites in 7 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-01-06.

Primary conditionDiabetes Mellitus, Type 2Registry: Diabetes MellitusReclassifiedWhy we changed it
Registry
Diabetes Mellitus — the first condition term the registry derived for this study.
ClinicalTrials.gg
Diabetes Mellitus, Type 2
Why
  1. The study's listed conditions name Diabetes Mellitus, Type 2, a narrower term within Diabetes Mellitus.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Novo Nordisk A/S · Phase 4, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
260
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-20

Among 76 studies testing Insulin Aspart in Diabetes Mellitus, Type 2 — 1 open to participants now, 2 under way, none of them phase 3. Insulin Aspart · Diabetes Mellitus, Type 2.

Enrollment
29th of 76
260 · median 163
Started
2003
with 7 others
Phase 4
34 of 76
1 open now
Registered
37th of 76
by date
Lead sponsor
60 of 76
Novo Nordisk A/S

Among the 76 studies testing Insulin Aspart in Diabetes Mellitus, Type 2, this one is the 29th largest by enrollment, is one of 8 that started in 2003, is one of 34 in phase 4, and was the 37th registered.

Diabetes Mellitus, Type 2

10,402 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

1 of the 76 studies testing Insulin Aspart in Diabetes Mellitus, Type 2 is open now. Recruiting first, the newest first:

About Insulin Aspart

Insulin Aspart: first FDA approval 2000 (NOVOLOG PENFILL), first EMA approval 1999. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 381 (43%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 76 studies testing Insulin Aspart in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

This trial is conducted in Europe. The aim of this trial is to investigate the efficacy on blood glucose control in type 2 diabetes.

03

Conditions studied

  • Diabetes
  • Diabetes Mellitus, Type 2

Browse trials for

04

In context

Diabetes Mellitus, Type 2 Reclassified

10,402 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.

This study's enrollment of 260 is above the median of 80 across 8,367 interventional studies indexed under Diabetes Mellitus, Type 2.

Browse Diabetes Mellitus, Type 2 studies →

Lead sponsor

Novo Nordisk A/S is the lead sponsor of 1,411 studies on the registry; 108 are open to participants now.

Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.

Compared within Diabetes Mellitus, Type 2, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Diabetes Mellitus. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Type 2 diabetes for at least 6 months
  • Insulin naive. Short term insulin treatment (7 days or less within the last 6 months) is allowed
  • Previous treatment with oral antidiabetic drugs for at least 4 months
  • Judged by the investigator to be eligible for an insulin analogue plus oral antidiabetic drug treatment regimen
  • below 40 kg/m2
  • between 7-12%
  • Able and willing to perform self-plasma glucose monitoring

Exclusion criteria

Exclusion Criteria:

  • The receipt of any other drug within 4 weeks before screening
  • A history of drug or alcohol abuse within the last 12 months
  • Severe, uncontrolled hypertension
  • Known or suspected allergy to trial products or related products
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

06

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
260 participants (actual)

Interventions

07

What researchers measure

Primary outcomes

  1. HbA1c

    Time frame: after 26 weeks of treatment

Secondary outcomes

  1. HbA1c

    Time frame: after 16 weeks of treatment

  2. Plasma glucose profiles

  3. Change in body mass index

  4. Incidence of hypoglycaemic episodes

  5. Safety profile

08

Study locations

54 sites
  • Novo Nordisk Investigational Site
    Ebreichsdorf, 2483, Austria
  • Novo Nordisk Investigational Site
    Feldkirch, 6807, Austria
  • Novo Nordisk Investigational Site
    Graz, 8036, Austria
  • Novo Nordisk Investigational Site
    Horn, A 3580, Austria
  • Novo Nordisk Investigational Site
    Oberpullendorf, 7350, Austria
  • Novo Nordisk Investigational Site
    Salzburg, 5010, Austria
  • Novo Nordisk Investigational Site
    Villach, A 9500, Austria
  • Novo Nordisk Investigational Site
    Waidhofen a.d. Thaya, A 3830, Austria
  • Novo Nordisk Investigational Site
    Brno, 65691, Czech Republic
  • Novo Nordisk Investigational Site
    Liberec, 46001, Czech Republic
  • Novo Nordisk Investigational Site
    Augsburg, 86150, Germany
  • Novo Nordisk Investigational Site
    Castrop-Rauxel, 44577, Germany
  • Novo Nordisk Investigational Site
    Deggingen, 73326, Germany
  • Novo Nordisk Investigational Site
    Duisburg, 47053, Germany
  • Novo Nordisk Investigational Site
    Erlangen, 91054, Germany
  • Novo Nordisk Investigational Site
    Eschweiler, 52249, Germany
  • Novo Nordisk Investigational Site
    Friedrichsthal, 66299, Germany
  • Novo Nordisk Investigational Site
    Fulda, 36037, Germany
  • Novo Nordisk Investigational Site
    Hamburg, 22119, Germany
  • Novo Nordisk Investigational Site
    Hamburg, 22177, Germany
  • Novo Nordisk Investigational Site
    Herne, 44623, Germany
  • Novo Nordisk Investigational Site
    Kippenheim, 77971, Germany
  • Novo Nordisk Investigational Site
    Lauffen, 74348, Germany
  • Novo Nordisk Investigational Site
    Leverkusen, 51377, Germany
  • Novo Nordisk Investigational Site
    Ludwigsburg, 71634, Germany
  • Novo Nordisk Investigational Site
    Ludwigshafen, 67059, Germany
  • Novo Nordisk Investigational Site
    Ludwigshafen, 67063, Germany
  • Novo Nordisk Investigational Site
    Mannheim, 68161, Germany
  • Novo Nordisk Investigational Site
    Mannheim, 68199, Germany
  • Novo Nordisk Investigational Site
    Marburg, 35037, Germany
  • Novo Nordisk Investigational Site
    Marburg, 35043, Germany
  • Novo Nordisk Investigational Site
    Mülheim, 45468, Germany
  • Novo Nordisk Investigational Site
    Neunkirchen, 66539, Germany
  • Novo Nordisk Investigational Site
    Ostercappeln, 49179, Germany
  • Novo Nordisk Investigational Site
    Pritzwalk, 16928, Germany
  • Novo Nordisk Investigational Site
    Rosenheim, 83022, Germany
  • Novo Nordisk Investigational Site
    Viernheim, 68519, Germany
  • Novo Nordisk Investigational Site
    Weil der Stadt, 71263, Germany
  • Novo Nordisk Investigational Site
    Weiskirchen, 66709, Germany
  • Novo Nordisk Investigational Site
    Witten, 58452, Germany
  • Novo Nordisk Investigational Site
    Witten, 58456, Germany
  • Novo Nordisk Investigational Site
    Budapest, 1041, Hungary
  • Novo Nordisk Investigational Site
    Eger, 3300, Hungary
  • Novo Nordisk Investigational Site
    Szekszárd, 7100, Hungary
  • Novo Nordisk Investigational Site
    Czestochowa, 42-200, Poland
  • Novo Nordisk Investigational Site
    Gdynia, 81-366, Poland
  • Novo Nordisk Investigational Site
    Lublin, 20 011, Poland
  • Novo Nordisk Investigational Site
    Otwock, 05-400, Poland
  • Novo Nordisk Investigational Site
    Poznan, 61-696, Poland
  • Novo Nordisk Investigational Site
    L'ubochna, 03491, Slovakia
  • Novo Nordisk Investigational Site
    Martin, 036 59, Slovakia
  • Novo Nordisk Investigational Site
    Celje, 3000, Slovenia
  • Novo Nordisk Investigational Site
    Ljubljana, 1000, Slovenia
  • Novo Nordisk Investigational Site
    Maribor, 2000, Slovenia
09

References and documents

Publications

  • Kann PH, Wascher T, Zackova V, Moeller J, Medding J, Szocs A, Mokan M, Mrevlje F, Regulski M. Starting insulin therapy in type 2 diabetes: twice-daily biphasic insulin Aspart 30 plus metformin versus once-daily insulin glargine plus glimepiride. Exp Clin Endocrinol Diabetes. 2006 Oct;114(9):527-32. doi: 10.1055/s-2006-949655. PubMed 17115351 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2003, a primary completion of Mar 2005 and a completion of Mar 2005. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 11, 2008
First posted
Feb 21, 2008
Start
Dec 2003
Primary completionActual
Mar 2005
CompletionActual
Mar 2005
Last update
Jan 6, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 6, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00619697
Lead sponsor
Novo Nordisk A/S
Responsible party
Sponsor
First posted
Feb 21, 2008
Start date
Dec 2003
Primary completion
Mar 2005
Completion
Mar 2005
Last update
Jan 6, 2017

Study contacts

Global Clinical Registry (GCR, 1452)
study director · Novo Nordisk A/S

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Insulin Aspart · Insulin Glargine · Metformin · Glimepiride

Start the discussion